Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety of using the combination of
decitabine and a cancer vaccine plus Hiltonol. The vaccine will be made from the subject's
blood cells and is designed to interact in the subject's body with cells that are programmed
to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma
Antigen Gene-A3 (MAGE-A3). The decitabine will be given to increase the amount and activity
of these cancer proteins on the surface of tumor cells to increase the possibility that the
vaccine will stimulate cells to act against the tumor cells. Subjects will be assessed to
determine how these tumors respond to the treatment.